Prescribing information

 

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

The NHS Long Term Plan acknowledges cardiovascular disease as a clinical priority2

of patients with cardiovascular disease in the UK have at least one comorbidity3,4

 

ASCVD, cardiovascular disease caused by the formation of atherosclerotic plaques, is the leading cause of morbidity and mortality worldwide.5

very high-risk ASCVD patients are Unable to reach 2019 ESC/EAS LDL-C goalson statins alone*6

 

Sustained lowering of LDL-C can help prevent the development and progression of ASCVD and associated cardiovascular events.5,7

 

Greater utilisation of adjunctive therapies is needed to help patients reach guideline-recommended LDL-C goals.6

There is a marked geographic variation in the diagnosis and treatment of high-risk cardiovascular conditions, such as elevated cholesterol.8

With the number of people dying prematurely from cardiovascular disease on the rise for the first time in 50 years,3  there has never been a more important time to address the risk this population faces

 

ADDRESSING THE ASCVD BURDEN

A collaboration between Novartis and NHS England delivered by the AAC and the AHSN Network uses a population health management approach to offer inclisiran treatment to at-risk ASCVD patients in primary care9

""

Population Health Management aims to address a wide range of real-world factors, like health inequalities, to improve health outcomes.10

The NHS Long Term Plan calls for a proactive population health approach to identify and treat patients with high-risk conditions to help prevent cardiovascular disease.11

 

This collaboration between Novartis and NHS England aims to contribute towards meeting the NHS Long Term Plan goals9,11

IN primary care where cardiovascular disease is mainly managed12

through the PROPOSED population health APPROACH

 

will provide access to treatment for patients with cardiovascular disease and elevated cholesterol not reaching their LDL-C goals on statins alone.9,11,13

 

Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.13
  • The effect of inclisiran on cardiovascular morbidity and mortality has not yet been determined.

 

""

Learn more about the inclisiran clinical trial data

 

 

For further information please refer to the Summary of Product Characteristics by clicking here

 

* Data from an 18-country European-wide cross-sectional, observational study of patients prescribed lipid-lowering therapy for primary of secondary prevention in primary or secondary care across Europe, including the UK (N=5,888).6 Treatment goals for very high-risk patients: LDL-C <1.4 mmol/L (<55 mg/dL) and ≥50% LDL-C reduction from baseline.14 As untreated lipid levels were not available, the authors could not quantify to what extent the ≥50% LDL-C reduction from baseline was achieved.6 All patients with documented ASCVD, either clinical or unequivocal on imaging, are considered very high risk.14

AAC Accelerated Access Collaborative; AHSN Academic Health Science Networks; ASCVD atherosclerotic cardiovascular disease.

References

  1. Gov.uk. Health Matters: Preventing cardiovascular disease. Available at: https://publichealthmatters.blog.gov.uk/2019/02/14/health-matters-preven... (Accessed: January 2021).

  2. NHS. Cardiovascular disease (CVD). Available at: https://www.england.nhs.uk/ourwork/clinical-policy/cvd/ (Accessed: January 2021).

  3. Heart UK. Prioritising the prevention of cardiovascular disease (CVD). Available at: https://www.heartuk.org.uk/downloads/health-professionals/heart-uk-cvd-p... (Accessed: January 2021).

  4. Tran J et al. PLoS Med 2018;15(3):e1002513.

  5. Ference BA et al. Eur Heart J 2017;38(32):2459–2472.

  6. Ray KK et al. Eur J Prev Cardiol 2020 (DOI: 10.1093/eurjpc/zwaa047).

  7. Ference BA et al. J Am Coll Cardiol 2018;72(10):1141–1156.

  8. NHS. Optimising treatment of high-risk conditions. Available at: https://www.england.nhs.uk/ltphimenu/cvd/optimising-treatment-of-high-ri... (Accessed: January 2021).

  9. Gov.uk. New heart disease drug to be made available for NHS patients. Available at: https://www.gov.uk/government/news/new-heart-disease-drug-to-be-made-ava... (Accessed: January 2021).

  10. NHS. Population Health Management Flatpack. Available at: https://imperialcollegehealthpartners.com/wp-content/uploads/2018/07/Pop... (Accessed: January 2021).

  11. NHS. The NHS Long Term Plan. Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term... (Accessed: January 2021).

  12. Hinton W et al. BMJ Open 2018;8(8):e020282.

  13. Leqvio® Summary of Product Characteristics.

  14. Mach F et al. Eur Heart J 2020;41(1):111–188.

Rate this content: 
No votes yet
UK | August 2021 | 141323
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]